Tin tức & Cập nhật

Chỉ hiển thị Multimedia
CheckMate 274 follow up data boost nivolumab potential for high-risk bladder cancer

CheckMate 274 follow up data boost nivolumab potential for high-risk bladder cancer

08 Mar 2023
Post-treatment neutrophil, lymphocyte counts offer clues to Hodgkin’s lymphoma prognosis

Post-treatment neutrophil, lymphocyte counts offer clues to Hodgkin’s lymphoma prognosis

08 Mar 2023 bởiJairia Dela Cruz

For patients with Hodgkin’s lymphoma who have completed a first-line chemotherapy regimen that includes doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), neutrophil and lymphocyte counts are predictive of disease prognosis, as reported in a study from Singapore.

Post-treatment neutrophil, lymphocyte counts offer clues to Hodgkin’s lymphoma prognosis

08 Mar 2023
Metformin plus oral contraceptives an alternative treatment for nonobese women with PCOS

Metformin plus oral contraceptives an alternative treatment for nonobese women with PCOS

07 Mar 2023

In the treatment of polycystic ovary syndrome (PCOS), the combination of metformin plus oral contraceptives appears to benefit women without obesity, inducing favourable effects on glucose metabolism with no further harm on lipid metabolism, according to the results of a meta-analysis.

Metformin plus oral contraceptives an alternative treatment for nonobese women with PCOS

07 Mar 2023
Local plus systemic therapies improve survival in HCC

Local plus systemic therapies improve survival in HCC

07 Mar 2023 bởiStephen Padilla

Combination therapy using yttrium 90 (Y90) radioembolization and sorafenib/nivolumab for patients with hepatocellular carcinoma (HCC), with hepatic vein (HV) or inferior vena cava (IVC) invasion, results in better outcomes, as indicated by increased response rates, overall survival (OS), and progression-free survival (PFS) benefits, a study has found.

Local plus systemic therapies improve survival in HCC

07 Mar 2023
Mesalamine shows modest benefit in IBS

Mesalamine shows modest benefit in IBS

06 Mar 2023

Treatment with mesalamine may only have modest efficacy for the global symptoms of irritable bowel syndrome (IBS), specifically IBS that causes increased diarrhoea, according to the results of a meta-analysis. However, the quality of evidence appears to be low.

Mesalamine shows modest benefit in IBS

06 Mar 2023